Support Measures Herald New Drug Rush In China?
This article was originally published in PharmAsia News
Executive Summary
Domestic developers of original drugs in China are beginning to gain clinical trial approvals (CTAs) in record times, especially for therapies to treat prevalent serious diseases such as cancers and hepatitis, helped by alliances with academia, the government push for innovation, and major CRO WuXi.